Loading…
← CockpitCompetitor Analysis › EPRX.TO Eupraxia Pharmaceuticals, Inc.Open in the cockpit ↗

Eupraxia Pharmaceuticals, Inc.EPRX.TOCompetitor analysis, valuation and peers

Canada · CAD·Health Care›Biotechnology
Momentum neutral 47
Mkt cap
$416M
US dollars, full cap
Free float
81%
of shares outstanding
$/day
$684,873
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-183.5 pp
WACC 10.5%
Hurdle
n/a
no reverse DCF
Next earnings
132 days
30 Mar 2027
Close · CADC$8.86
1D-6.2%
1W-22.6%
1M-17.4%
3M-8.8%
6M+1.4%
YTD-14.2%
1Y-5.6%
ATR %8.8%
52w lowhigh32.3% off high

What Eupraxia Pharmaceuticals does

Employees: 49

Eupraxia Pharmaceuticals at a glance

Size Eupraxia Pharmaceuticals (EPRX.TO) is a Canada Health Care company (Biotechnology) with a market value of $416M, the 352nd largest of 405 Canada companies the cockpit tracks. Shares closed at C$8.86 on 18 Nov 2026.

Performance Over six months the shares gained 1.4%, against -23.0% for the median peer and +1.1% for the Canada market (cap-weighted) — 3rd highest of 21 in its peer set.

Capital Return on invested capital runs 183.5 points below its cost of capital (10.5% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026EPRX.TO 91Peer median 77
Six months, rebased to 100: Eupraxia Pharmaceuticals against the median of its 20 peers (local-currency closes).

Eupraxia Pharmaceuticals financials

Reported figures in CAD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueC$0C$0C$0C$0C$0
Revenue growth—————
Gross profit-C$669,081-C$332,159-C$235,248-C$209,911-C$193,273
EBITDA-C$91.4M-C$53.4M-C$36.8M-C$37.7M-C$23.4M
Net income-C$82.0M-C$53.9M-C$34.9M-C$38.1M-C$23.3M
Free cash flow-C$62.6M-C$40.7M-C$41.2M-C$28.0M-C$19.1M
Capital expenditureC$1.15MC$822,929C$142,787C$99,036C$308,370
Total debtC$4.86MC$211,592C$103,348C$13.8MC$10.5M

Quarterly statements and history in the cockpit →

Eupraxia Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%0%688163456160CADL476830688238699868831733786547671211672509PRTA68809817892480300683603739000710IRLAEPRX.TO6-month return →1-month return →
Up and to the right = strong over both horizons. Eupraxia Pharmaceuticals is the large dot.

Eupraxia Pharmaceuticals competitors and peer comparison

How Eupraxia Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Eupraxia Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureEPRX.TOPeer medianRank in peer set
1-month return-17.4%-13.4%7th lowest of 21
6-month return+1.4%-23.0%3rd highest of 21
Distance from 52-week high-32.3%-43.6%3rd highest of 21
ROIC minus cost of capital-183.5 pp-9.3 pplowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%10.6×n/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%908.6×n/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%215.1×n/an/a
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%10.3×n/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%1.0×-15.3%+197.3%
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%2.9×4.0%-62.3%
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%14.6×n/an/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%1.9×-18.8%-36.1%
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%10.9×n/an/a
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/an/an/an/a
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%5.2×n/an/a
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a

Questions

Which companies are Eupraxia Pharmaceuticals's closest peers?
The cockpit's peer set: Shanghai Serum Bio-Technology (688163.SS), G2GBIO (456160.KS), Candel Therapeutics (CADL), Rznomics (476830.KS), Shanghai Obio Technology (Group) (688238.SS), Edding Genor (6998.HK), Shanghai ZJ Bio-Tech (688317.SS), Hanx Biopharmaceuticals (Wuhan) (3378.HK).
How has Eupraxia Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned +1.4% against -23.0% for the median peer; over one year -5.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.